View ValuationOncoinvent 향후 성장Future 기준 점검 2/6Oncoinvent (는) 각각 연간 20.9% 및 47.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -11.1% 로 예상됩니다.핵심 정보20.9%이익 성장률-21.00%EPS 성장률Pharmaceuticals 이익 성장24.2%매출 성장률47.7%향후 자기자본이익률-11.10%애널리스트 커버리지Low마지막 업데이트29 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).공고 • Jun 18Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.공고 • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.공고 • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.Board Change • Dec 30No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Dec 03Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million.Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million. Security Name: Shares Security Type: Common Stock Securities Offered: 260,000,000 Price\Range: NOK 0.5 Transaction Features: Rights Offering공고 • Nov 01Oncoinvent ASA Announces CFO Changes, Effective on or Around January 15, 2025Oncoinvent ASA announced the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.이익 및 매출 성장 예측DB:7BG - 애널리스트 향후 추정치 및 과거 재무 데이터 (NOK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028101-58-57-57212/31/202726-165-165-162212/31/202625-182-169-164112/31/202528-155-130-130N/A9/30/202524-131-108-107N/A6/30/202520-107-86-84N/A3/31/202514-123-88-86N/A12/31/20248-140-90-88N/A9/30/20249-155-120-116N/A6/30/20246-165-149-142N/A3/31/20246-151N/AN/AN/A12/31/20236-144-165-138N/A9/30/20236-134N/AN/AN/A6/30/20236-122N/AN/AN/A3/31/20236-115N/AN/AN/A12/31/20226-106-93-89N/A9/30/20227-93N/AN/AN/A6/30/202210-89N/AN/AN/A3/31/202211-86N/AN/AN/A12/31/202111-80N/AN/AN/A9/30/202110-76N/AN/AN/A6/30/20219-68N/AN/AN/A3/31/202111-63N/AN/AN/A12/31/202010-59N/AN/AN/A9/30/202013-51N/AN/AN/A6/30/202013-48N/AN/AN/A3/31/202010-44N/AN/AN/A12/31/201911-42N/AN/AN/A9/30/201910-39N/AN/AN/A6/30/20199-41N/AN/AN/A3/31/201911-36N/AN/AN/A12/31/201810-33N/AN/AN/A9/30/20186-32N/AN/AN/A6/30/20187-25N/AN/AN/A3/31/20185-23N/AN/AN/A12/31/20176-16N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 7BG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 7BG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 7BG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 7BG 의 수익(연간 47.7%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 7BG 의 수익(연간 47.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 7BG는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/01 22:14종가2026/07/31 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oncoinvent ASA는 1명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Geir HolomDNB Carnegie
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).
공고 • Jun 18Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.
Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.
공고 • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.
공고 • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.
Board Change • Dec 30No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Dec 03Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million.Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million. Security Name: Shares Security Type: Common Stock Securities Offered: 260,000,000 Price\Range: NOK 0.5 Transaction Features: Rights Offering
공고 • Nov 01Oncoinvent ASA Announces CFO Changes, Effective on or Around January 15, 2025Oncoinvent ASA announced the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.